myLaminin Perspectives

Secure research collaboration is critical for universities, hospitals, CROs, biotech, and pharmaceutical organizations across Canada and the United States. As clinical trial data, IP, and regulatory information are shared, trust is the foundation. This article explores why secure research collaboration platforms matter and how myLaminin enables SOC 2 Type II compliant, patented collaboration across North America while protecting sensitive research data and accelerating discov

Five years ago, myLaminin began with a single idea. Today, it has evolved into a connected research ecosystem supporting the complete research lifecycle—from grant submission through publication. Discover how one conversation with a Canadian U15 university transformed our vision, how researchers co-designed our platform, and how myLaminin became a sovereign Research Data Management (RDM) and Clinical Trial Management System (CTMS) built for active science.

The new ICH E6(R3) guidelines are transforming clinical research worldwide, requiring Quality-by-Design, risk-based oversight, and validated digital systems. Discover how myLaminin's co-designed Clinical Trial Operations (CTOps) and CTMS platform helps research teams, principal investigators, administrators, and compliance professionals streamline operations, strengthen data integrity, improve audit readiness, and meet evolving global regulatory requirements with confidence.

Learn the differences between CTMS, EDC, and eTMF and how these essential clinical trial systems work together to improve research operations, data quality, regulatory compliance, and study efficiency. This guide explains the role of each platform, their integration across the clinical trial lifecycle, and how myLaminin's Research Data Management platform combines CTMS capabilities, participant management, eTMF, protocol management, audit trails, and 21 CFR Part 11 compliant

Discover how Clinical Trial Management Systems (CTMS) help academic research institutions improve compliance, reduce administrative burden, accelerate study start-up, and support ICH E6(R3)-aligned clinical trial operations.